Log In Sign up
The largest database of trusted experimental protocols
> Disorders > Mental or Behavioral Dysfunction > Dysarthria

Dysarthria

Dysarthria refers to a speech disorder characterized by impaired articulation and pronunciation, often resulting from neurological conditions or diseases.
This AI-powered platform, PubCompare.ai, helps researchers and clinicians efficiently locate the most effective protocols and treatments for dysarthria from published literature, preprints, and patents.
By empowering users to compare and identify the optimal interventions, the platform streamlines the research process and accelerates the discovery of effective managmeent strategies for this speech impairment.
Experience the power of AI-driven protocol comparisons to advance your dysarthria research today.

Most cited protocols related to «Dysarthria»

1
Clinicopathological Characteristics of ALS Cohort
Cited 34 times
We included 76 patients with a clinical diagnosis of ALS (Table 1) in accordance with modified El Escorial Criteria15 and a confirmed neuropathological diagnosis of ALS, who underwent autopsy in the Center for Neurodegenerative Disease Research (CNDR) at the University of Pennsylvania between 1985 and 2012. Informed written consent was obtained previously from all patients or for autopsy cases from their next of kin. Detailed clinical characteristics (age at onset, age at death, site of onset, disease duration, ALS global disease severity as measured by a functional rating score [ALSFRS-R],16 (link) the Mini Mental Status Examination,17 (link) and gender), were ascertained from an integrated clinical and autopsy database, as described previously,18 and by retrospective chart review of clinical visits within the University of Pennsylvania Health System (Table 1).
The majority of the ALS patients were seen by two neurologists (LE, LM). We excluded all ALS cases in the CNDR Brain Bank (N=35) for which clinical data relating to site of onset or disease duration was incomplete or equivocal. Also excluded were 6 cases, for which ≥ 3/22 CNS regions examined (see below) were unavailable, and 2 cases lacking pTDP-43 pathology, leaving a cohort of N=76 (N=30 females, N=46 males; age range 42-87 years; mean age ± SD: 63.0 ± 10.6 years from a total of 119 autopsy cases (Tables 1-2). For the subjects with missing data, their gender, disease duration, and age of death were compared to the other cases and no differences were found (data not shown). Different ALS syndromes were defined according to clinical onset of disease: cervical lower motor neuron (CLMN) ALS, lumbar lower motor neuron (LLMN) ALS, lumbar upper motor neuron (LUMN) ALS, bulbar lower motor neuron (BLMN) ALS, and bulbar upper motor neuron (BUMN) ALS.19 None of the cases in the cohort had cervical UMN onset of disease (Table 1). Unless otherwise specified, results of clinical testing used in this study were from the visits at initial presentation or disease onset (first occurrence of paresis or bulbar symptoms, e.g., dysarthria, dysphagia) as well as the visit most proximate to death, i.e., occurring within 3 months of death. Of the ALS cases included here, 5 (6.6%) had a clinical history of dementia (ALS-D) (Table 2), and met criteria for FTLD.20 (link)-22 (link)
Brettschneider J., Del Tredici K., Toledo J.B., Robinson J.L., Irwin D.J., Grossman M., Suh E., Van Deerlin V.M., Wood E.M., Baek Y., Kwong L., Lee E.B., Elman L., McCluskey L., Fang L., Feldengut S., Ludolph A.C., Lee V.M., Braak H, & Trojanowski J.Q. (2013). Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Annals of neurology, 74(1), 20-38.
Publication 2013
Autopsy Brain Diseases Cervix Diseases Deglutition Disorders Dementia Diagnosis Dysarthria Females Frontotemporal Lobar Degeneration Lumbar Region Males Medulla Oblongata Mini Mental State Examination Motor Neurons Neck Neurodegenerative Disorders Neurologists Paresis Patients Syndrome
2
Diagnosing Primary Progressive Apraxia of Speech
Cited 29 times
Between 1 July 2010 and 31 July 2011 we recruited all patients who presented to the Department of Neurology with a speech and language disorder suspected to be secondary to a degenerative process. Only subjects over the age of 18, with an informant to provide independent evaluation of functioning, and who spoke English as their primary language, were included. All subjects underwent detailed speech and language examination, neurological evaluation, neuropsychological testing and neuroimaging analysis over a span of 48–72 h. Clinical diagnosis of PPAOS was rendered based solely on data from speech and language assessments without any reference to neurological, neuropsychological or neuroimaging results at a consensus meeting held 1–2 months after enrolment. All subjects had video and audio recordings of their entire comprehensive, formal speech and language assessment, as well as general conversation and performance on a measure of oral praxis.
Diagnosis was made according to operational definitions, after review of the video and audio recordings and review of speech and language test scores as described below. In order to be included in this study all subjects must have been diagnosed with PPAOS; any evidence suggesting aphasia could not be more than equivocal. Dysarthria could be present. Therefore, any subject with even mild (but unequivocal) evidence of aphasia was excluded. Subjects with concurrent illnesses that could account for the speech deficits, such as traumatic brain injury, stroke or developmental syndromes, and subjects meeting criteria for another neurodegenerative disease, such as Alzheimer’s type dementia (McKhann et al., 1984 (link)), dementia with Lewy bodies (McKeith et al., 2005 (link)), behavioural variant frontotemporal dementia (Neary et al., 1998 (link)), probable progressive supranuclear palsy (Litvan et al., 1996 (link)), corticobasal syndrome (Boeve et al., 2003 (link)), multiple system atrophy (Gilman et al., 2008 (link)), or motor neuron degeneration (Brooks et al., 2000 (link)) were excluded. Subjects were also excluded if MRI was contraindicated (metal in head, cardiac pace maker, etc.), if there was severe claustrophobia or conditions that might confound brain imaging studies (e.g. structural abnormalities, including subdural haematoma or intracranial neoplasm), or if they were medically unstable or were on medications that might affect brain structure or metabolism, (e.g. chemotherapy).
During this period, 40 subjects were screened of which 37 were recruited and three excluded (Supplementary Fig. 1). One subject was excluded due to a tiny chronic lacunar infarct in the left centrum semiovale and left subinsular white matter, one as a result of having a pacemaker, and one who was determined to meet clinical criteria for Alzheimer’s disease (McKhann et al., 1984 (link)).
The study was approved by the Mayo Clinic institutional review board and all subjects consented for enrolment into the study.
Josephs K.A., Duffy J.R., Strand E.A., Machulda M.M., Senjem M.L., Master A.V., Lowe V.J., Jack CR J.r, & Whitwell J.L. (2012). Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 135(5), 1522-1536.
Publication 2012
Alzheimer's Disease Aphasia ARID1A protein, human Brain Cerebrovascular Accident Claustrophobia Congenital Abnormality Corticobasal Degeneration Dementia Dysarthria Ethics Committees, Research Head Heart Hematoma, Subdural Infarction, Lacunar Language Disorders Language Tests Lewy Body Disease Metabolism Metals Multiple System Atrophy Neoplasms, Intracranial Nerve Degeneration Neurodegenerative Disorders Neurologic Examination Pacemaker, Artificial Cardiac Patients Pharmaceutical Preparations Pharmacotherapy Pick Disease of the Brain Progressive Supranuclear Palsy Speech Syndrome Traumatic Brain Injury Wallerian Degeneration White Matter
3
Comprehensive Language and Speech Evaluation Protocol for Neurodegenerative Disorders
Cited 20 times
The Western Aphasia Battery-revised Part 1 (Kertesz, 2007 ) served as the primary measure of global language ability; the Writing Output subtest from Part 2 of the Western Aphasia Battery served as a speech-independent measure of language expression. A 22-item version of Part V of DeRenzi and Vignolo’s Token Test (DeRenzi and Vignolo, 1962 (link)) served as a challenging measure of verbal comprehension ability (Wertz et al., 1971 ), and the 15-item Boston Naming Test (Lansing et al., 1999 (link)) as a sensitive measure of confrontation-naming ability. Action (verb) Fluency (Woods et al., 2005 (link)) and Letter (FAS) Fluency (Loonstra et al., 2001 (link)) tasks served as indices of rapid-word retrieval ability for those categories. A score >2 standard deviations (SD) below the mean on all language tests with published or derived mean and standard deviation was considered abnormal.
Judgements about motor speech abilities were based on all spoken language tasks of the Western Aphasia Battery plus additional speech tasks that included vowel prolongation, speech alternating motion rates (e.g. rapid repetition of ‘puhpuhpuh…’), speech sequential motion rates (e.g. rapid repetition of ‘puhtuhkuh’), word and sentence repetition tasks and a conversational speech sample. Sixteen speech characteristics (Box 1), consistent with current criteria for AOS diagnosis (Duffy, 2005 ; Wambaugh et al., 2006 ; McNeil et al., 2009 ), or observations of characteristics of AOS associated with neurodegenerative disease (Duffy, 2006 ), and selected to cast a wide net for capturing features of the disorder, were rated on an AOS rating scale, which provided a description of AOS characteristics and their prominence. Ratings were based on the following scale: 0 = not present; 1 = detectable but not frequent; 2 = frequent but not pervasive; 3 = nearly always evident but not marked in severity; 4 = nearly always evident and marked in severity. Normal cut-off values for the summed ratings were based on the performance of 14 subjects with PPA for whom there was no clinical evidence of AOS. A global AOS severity rating (0–4) was also made.
The same speech tasks were also judged for the presence or absence of dysarthria, which was rated on a 0–4 severity scale. An eight-item measure of non-verbal oral praxis, with responses to each item rated on a 0–4 scale (with a score of 4 representing best/normal performance), served as a quantitative index of non-verbal oral apraxia. A global judgement about the presence or absence of non-verbal oral apraxia was also made.
Quantitative scores and video recordings of crucial aspects of the test protocol were reviewed for all subjects by two authors (J.R.D. and E.A.S.) who made independent judgements about the presence or absence of aphasia, AOS, dysarthria and non-verbal oral apraxia, and the severity of each disorder. Independent agreement about the presence or absence of aphasia and presence or absence of AOS and non-verbal oral apraxia was achieved for 11/12 subjects. Discussion regarding the presence or absence of AOS was required for consensus for Subject 8, whose AOS was very mild and the least severe among the 12 subjects. Independent agreement regarding the presence or absence of dysarthria was 100%. Both judges agreed after discussion that the evidence for spastic dysarthria was equivocal for Subjects 1 and 3, and that evidence of a hypokinetic component for Subject 7 was equivocal.
Josephs K.A., Duffy J.R., Strand E.A., Machulda M.M., Senjem M.L., Master A.V., Lowe V.J., Jack CR J.r, & Whitwell J.L. (2012). Characterizing a neurodegenerative syndrome: primary progressive apraxia of speech. Brain, 135(5), 1522-1536.
Publication 2012
Aphasia Apraxia, Oral Apraxia, Verbal CD3EAP protein, human Diagnosis Dysarthria Language Tests Neurodegenerative Disorders Speech
4
Identifying ALS Staging Milestones
Cited 20 times
Patients were classified as having limb, bulbar or diaphragmatic onset ALS. For the purposes of analysis, those with diaphragmatic onset were classified with those with limb onset because of the common spinal basis of lower motor neuron degeneration. ALS milestones for investigation as potential staging criteria were selected on the basis of being easily clinically available by being routinely collected at any clinical visit, straightforward to define in terms of presence or absence of involvement, and useful for phenotypic classification (Wijesekera et al., 2009 (link)). Milestones were defined as symptom onset (functional involvement by weakness, wasting, spasticity, dysarthria or dysphagia of one CNS region defined as bulbar, upper limb, lower limb or diaphragmatic), diagnosis, functional involvement of a second region, functional involvement of a third region, needing gastrostomy and non-invasive ventilation. As wasting was almost always associated with weakness, and for patients with ALS spasticity manifests as weakness, we did not differentiate between those patients whose onset was not weakness, but rather spasticity or wasting without weakness. Timing of involvement was based on the date of onset of symptoms and dates of development of functionally significant symptoms in a second and third region, which were gathered from the clinical history. Diagnosis was defined as a confirmed diagnosis of ALS made either by the referring neurologist or at the tertiary centre, as recorded in the case records. The need for gastrostomy was defined as the time gastrostomy or nasogastric feeding was provided or refused. The need for non-invasive ventilation was defined as the time non-invasive ventilation was provided, trialled or refused.
Milestone timings were standardized as proportions of time elapsed through the disease course using information from patients who had died by dividing time to a milestone by disease duration, a similar method to that used in a previous study of timings of medical interventions (Bromberg et al., 2010 (link)). Thus the time to each milestone was a value between 0 and 1, with 0 being symptom onset and 1 being death. Date of death was ascertained by clinic records, death certificates and contact with the patient's registered general practitioner. The highest milestone recorded at last follow-up was used. Riluzole use was also recorded and defined as any use longer than 2 weeks.
Roche J.C., Rojas-Garcia R., Scott K.M., Scotton W., Ellis C.E., Burman R., Wijesekera L., Turner M.R., Leigh P.N., Shaw C.E, & Al-Chalabi A. (2012). A proposed staging system for amyotrophic lateral sclerosis. Brain, 135(3), 847-852.
Publication 2012
Asthenia Deglutition Disorders Diagnosis Disease Progression Dysarthria Gastrostomy Lower Extremity Medulla Oblongata Motor Neurons Muscle Spasticity Neurologists Noninvasive Ventilation Patients Phenotype Riluzole Upper Extremity
5
Chronic Aphasia Therapy Outcomes
Cited 8 times
Thirty-one individuals (20 male) with chronic aphasia following a left-hemisphere (LH) stroke were recruited from the greater Boston and Chicago areas. Ten of these individuals served as natural history controls in that they were tested at baseline and, again after a three- to six-month period without treatment. Twenty-seven of these individuals, five of whom started out in the natural history control group (BU08/BUc01, BU19/BUc02, BU16/BUc05, BU24/BUc06), participated in up to 12 weeks of therapy and thus comprised the treatment group in this study. See Table 1 for demographic information for both treatment and natural history control participants (i.e., age, months post onset (MPO), cognitive-linguistic severity, aphasia type, apraxia of speech (AOS) status, baseline performance on the confrontation naming screener, treatment/generalization effect sizes (ES), and average accuracy on trained and untrained categories at pre- and post-treatment). All participants demonstrated adequate vision and hearing (i.e., passed screening at 40db HL bilaterally/or able to be corrected with increased volume); were English-proficient pre-morbidly (per self or family report); presented with stable neurological and medical status; and were not receiving concurrent individual speech and language therapy. None of the participants had neurodegenerative disease or active medical conditions that affected their ability to participate in the study. Written consent to participate in the study was obtained in accordance with the Boston University Institutional Review Board (IRB) protocols for 29 patients and per the Northwestern University IRB protocols for two participants.1 Of note, data from the 27 individuals in the treatment group were also included in a separate study examining the influence of baseline language and cognitive skills on treatment success (Gilmore, Meier, Johnson, & Kiran, 2018 , under revision).
The diagnosis of aphasia was determined through administration of the WAB-R. Participants were administered a180-item confrontation naming screener consisting of items from five semantic categories (i.e., birds, vegetables, fruit, clothing and furniture) including 36 exemplars of each category, and further divided into half-categories by typicality (i.e., 18 typical; 18 atypical). During the screener, pictures were presented in random order and participants were instructed to name the items. In addition to production of the intended target, responses were considered correct if they were self-corrections, altered due to dialectal differences, distortions or substitutions of one phoneme, and/or produced correctly following a written self-cue. Participants were included in the study if they demonstrated stable performance of ≤ 65% average accuracy in two different half-categories (e.g., Atypical Birds, Typical Clothing) across multiple baselines of the screener. Individuals with AOS were enrolled in the study as long as they were stimulable to produce targets with a verbal model from a clinician. The AOS rating in Table 1 was based on the Screen for Dysarthria and Apraxia of Speech (S-DAOS) (Dabul, 2000 ) and clinical judgment. In cases when AOS severity per the S-DAOS and primary clinician’s judgment did not align (e.g., patients with phonological errors judged as having AOS on S-DAOS), at least two trained speech-language pathologists (SLP) judged absence or presence of AOS based on pre-treatment speech samples.
Gilmore N., Meier E.L., Johnson J.P, & Kiran S. (2018). Typicality-based semantic treatment for anomia results in multiple levels of generalization. Neuropsychological rehabilitation, 30(5), 802-828.
Publication 2018
Aphasia Apraxia of Phonation Aves BaseLine dental cement Cerebrovascular Accident Clinical Reasoning Cognition Diagnosis Dysarthria Ethics Committees, Research Fruit Generalization, Psychological lauric acid Males Neurodegenerative Disorders Pathologists Patients Specimen Handling Speech Speech Therapy Vegetables Vision

Most recents protocols related to «Dysarthria»

1
Neurological Function Evaluation Protocol
Neurological function evaluation: the NIHSS scale was used to evaluate the language ability, dysarthria, upper limb movement, and lower limb movement and so on.[12 ]
Wang Y., Huang C., Tian R, & Yang X. (2023). Target temperature management and therapeutic hypothermia in sever neuroprotection for traumatic brain injury: Clinic value and effect on oxidative stress. Medicine, 102(10), e32921.
Publication 2023
Dysarthria Lower Extremity Movement Neurologic Examination Upper Extremity
2
Telephone Survey of Stroke Characteristics
A trained research assistant administered the telephone survey to participants over the phone. After obtaining verbal consent, a 20-min telephone survey was conducted.
Patient characteristics included baseline demographic characteristics (age, gender, and marital status), socioeconomic status (per capita monthly household income and education level), behavioral habits (smoking and alcohol consumption), history of comorbid chronic diseases (hypertension, diabetes, dyslipidemia, coronary heart disease, and atrial fibrillation), the stroke type, the degree of functional dependence at discharge, limb muscle strength, stroke complications (dysarthria, visual deficiency, swallowing disturbances, reduced bladder control, and sensory disturbances), and the occupational type before the onset. Among them, demographic characteristics, the history of comorbid chronic diseases, the stroke type, the degree of functional dependence at discharge, limb muscle strength, and stroke complications were obtained from the electronic medical record. Moreover, socioeconomic status, behavioral habits, and occupational type before the onset was obtained during the 20-min interview.
Age was categorized into 25–34, 35–44, and 45–55. The education level was categorized into primary school (Elementary school and below), junior high school, secondary school, or college and above. Family per capita monthly income (income level), which is equal to family income divided by the number of family members, was categorized as “ <1000,” “1001–3000,” “3001–5000,” and “>5000.” The degree of functional dependence is scored according to the activities of daily living (ADL) scale: 100 points mean no dependence, 60–99 points mean mild dependence, 40–60 points mean moderate dependence, and <40 points mean severe dependence. The muscle strength of the left upper limb, the right upper limb, the left lower limb, and the right lower limb was evaluated with a clinical examination (levels 0–5). If the muscle strength of the limb is below grade 4, the limb is considered dysfunctional.
Pan X., Wang Z., Yao L, & Xu L. (2023). The reasons for not returning to work and health-related quality of life among young and middle-aged patients with stroke: A cross-sectional study. Frontiers in Neurology, 14, 1078251.
Full text: Click here
Publication 2023
Atrial Fibrillation Cerebrovascular Accident Diabetes Mellitus Disease, Chronic Dysarthria Dyslipidemias Family Member Gender Head Heart Disease, Coronary High Blood Pressures Households Lower Extremity Muscle Strength Patient Discharge Patients Physical Examination Sensory Disorders Upper Extremity Urinary Bladder
3
Asleep-Awake-Asleep Craniotomy with Cortical Mapping
We adopted the asleep-awake-asleep protocol for awake craniotomy with direct brain stimulation, and tumor removal was performed on all 80 patients. After removing the bone flap, the patient was awakened, and cortical mapping was used to identify language and motor areas. The StealthStation S7 neuronavigation (Medtronic Navigation) was applied in each case to plan the surgical incision and identify tumor margins related to brain sulcal and gyral surface structures. Intraoperative ultrasound was also used to help distinguish the tumor boundaries. Before the brain shifts, numerical and letter tags were placed along the cortical tumor margins.
A biphasic current (pulse frequency 60 Hz; single pulse duration 0.5 msec) was delivered through a bipolar stimulator with a 5 mm interelectrode distance for cortical stimulation. The initial setting was 1 mA, gradually increasing the amplitude in 0.5-1 mA increments until reproducible response (motor or sensory function) was obtained or discharge potentials were detected (baseline 1 mA, maximum 8 mA). Stimulation was applied for 4 s at the indicated areas, with a pause of 2-4 s between stimulations. Cortical and subcortical regions were identified using a similar stimulation protocol.
Sensorimotor mapping was first performed to confirm the positive responses (movement and/or paresthesia). Stimulations were repeated at least three times to confirm the positive sites. A negative sensorimotor area was also indicated when no response occurred in the area of interest.
For language mapping, the patient was asked to perform three verbal tasks: counting (regular rhythm, from 1 to 10, repetitively), picture naming (DO80) and word-reading task to identify the essential cortical sites which might be inhibited by stimulation. During the picture naming task, the patient was asked to read a short phrase in Chinese as “this is a ……” before naming each picture to check whether seizures were generated and induced speech arrest if the patient could not name the picture successfully. During the word-reading task, the patient was asked to read Chinese words presented on the computer screen. The duration of each stimulation was also about 4 s. Between each actual stimulus interval, at least one picture was presented without stimulation, and no site was stimulated twice in succession. The types of language disturbances (speech arrest, dysarthria, phonetic/phonemic/semantic paraphasia, anomia, and alexia) found intraoperatively were classified by neuropsychological experts in our department.
By applying the same stimulation parameters, the glioma was removed with alternating resection and electrostimulation for subcortical functional mapping. The patient continuously performed the above tasks throughout glioma resection.
Wang Y., Guo S., Wang N., Liu J., Chen F., Zhai Y., Wang Y., Jiao Y., Zhao W., Fan C., Xue Y., Gao G., Ji P, & Wang L. (2023). The clinical and neurocognitive functional changes with awake brain mapping for gliomas invading eloquent areas: Institutional experience and the utility of The Montreal Cognitive Assessment. Frontiers in Oncology, 13, 1086118.
Full text: Click here
Publication 2023
Alexia Anomia Bones Brain Cardiac Arrest Chinese Cortex, Cerebral Craniotomy Dysarthria Glioma Motor Cortex Movement Neoplasm, Adrenal Cortex Neoplasms Neuronavigation Paresthesia Patient Discharge Patients Pulse Rate Seizures Sensorimotor Cortex Speech Surgical Flaps Surgical Wound Ultrasonics
4
Comprehensive Neurological and Cognitive Assessment Protocol for Brain Surgery Patients
All patients underwent detailed neurological and psychological evaluations before surgery. Two neurosurgeons completed a neurological function assessment and motor function was scored using a standard muscle strength score ranging from 0 to 5 (0, complete paralysis; 5, entirely normal strength). Neuropsychologists evaluated the general cognitive function of the patients using a brief psychiatric examination. All patients were assessed for handedness using a standardized questionnaire (Edinburgh Handedness Inventory) and were examined with the Mini-Mental State Examination (MMSE). Language function was assessed using an aphasia screening chart, a dysarthria chart, and naming of images. Aphasia screening included oral, written, and sign language comprehension and expression. The dysarthria chart was evaluated by orofacial movement, vowels, and consonant articulation, with a total score of 14 points. The picture naming task was to name 80 black and white pictures with a naming accuracy rate ≥95% being normal. The grade of neurological deficits are presented in Table 1. Within 3 days before surgery, MRI was performed using a 3.0-T scanner (GE HealthCare, Chicago, IL, USA) to obtain T1, T2, T2-fluid attenuated inversion recovery (FLAIR), gadolinium enhanced diffuse tensor imaging (DTI), magnetic resonance spectrum (MRS) and perfusion-weighted sequences. All patients were informed in detail about the risks of surgery and the intraoperative stimulation monitoring procedure was performed by a trained nurse responsible for intraoperative motor and language testing.
Yao S., Yang R., Du C., Jiang C., Wang Y., Peng C, & Bai H. (2023). Maximal safe resection of diffuse lower grade gliomas primarily within central lobe using cortical/subcortical direct electrical stimulation under awake craniotomy. Frontiers in Oncology, 13, 1089139.
Full text: Click here
Publication 2023
Aphasia Cognition Dysarthria Gadolinium Inversion, Chromosome Joints Mini Mental State Examination Movement Muscle Strength Neurologic Examination Neurosurgeon Nuclear Magnetic Resonance Nurses Operative Surgical Procedures Patients Perfusion
5
Predicting Early Prognosis in Acute Guillain-Barré Syndrome
A retrospective design was used to study patients with confirmed acute GBS who were admitted to the Department of Neurology at the Beijing Tongren Hospital of Capital Medical University from 2007 to 2021. (1) Inclusion criteria: (i) met the diagnostic criteria of the 2019 Chinese Guillain-Barré Syndrome Diagnosis and Treatment Guidelines developed by the Chinese Medical Association [3 ]; (ii) first-onset admission. (2) Exclusion criteria: (i) patients with combined definite intracranial lesions; (ii) patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP); (iii) patients who could not be excluded from peripheral neuropathy caused by other etiologies; (iv) patients with incomplete case data.
Measured characteristics included gender, age at onset, antecedent infection (whether diarrhea, upper respiratory tract infection, pulmonary infection, or other unexplained infection occurred within 4 weeks prior to onset), cranial nerve involvement (presence of ophthalmoplegia, facial palsy, dysarthria, dysphagia, weak neck, and shoulder rotation), presence of pulmonary infection (symptoms such as cough, sputum, and fever during the course of the disease, and confirmation with high-resolution computed tomography (HRCT) of the lungs). Mechanical ventilatory support, hyponatremia, hypoalbuminemia, impaired fasting glucose and the peripheral blood neutrophil-to-lymphocyte ratio (NLR) were analyzed as alternative influencing factors. Peripheral blood was collected from all patients within 24 h of admission. Plasma sodium < 135 mmol/L was considered as combined hyponatremia. Fasting plasma glucose (FPG) > 6.1 mmol/L was considered impaired fasting glucose. Plasma albumin < 35 g/L was defined as hypoalbuminemia. An elevated NLR was defined as an NLR value > 2.135.
The GBS disability score developed by Hughes (Hughes functional grading scale, HFGS) [4 (link)] et al. was used for assessment on the day of discharge: 0 represented a completely normal state; 1 represented mild signs or symptoms and ability to run; 2 represented the ability to walk ≥ 10 m alone but the inability to run; 3 represented the ability to walk 10 m in open space with assistance; 4 represented a bedridden or wheelchair bound state; 5 represented a requirement of assisted ventilatory support; and 6 referred to death. Those with GBS disability scores > 3 at discharge were considered to have a poor early prognosis and those with GBS scores ≤ 3 had better early prognoses.
SPSS 23.0 and MedCalc statistical software were used for the analysis. The χ2 test or Fisher's exact test was used to compare groups of count data. (1) Univariate analysis was used to derive risk factors for poorer early prognosis (HFGS score > 3) in patients with GBS. (2) Statistically significant (P < 0.05) influencing factors obtained from this analysis were then included in a multivariate logistic regression analysis, and regression coefficients were calculated. (3) The integer value closest to the regression coefficient was used as the influencing factor score value in order to establish an early prognostic scoring system. (4) The predictive value of the scoring system was evaluated by plotting the receiver operating curve (ROC) curve: the area under the ROC curve (AUC) was calculated, the appropriate cut-off value was selected, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated.
Di X., Wang J., Li L, & Liu L. (2023). Establishment of a single-center-based early prognostic scoring system for Guillain-Barré syndrome. BMC Neurology, 23, 97.
Full text: Click here
Publication 2023
BLOOD Chinese Cough Cranial Nerves Debility Deglutition Disorders Diagnosis Diarrhea Disabled Persons Disease Progression Dysarthria Fever Gender Glucose Guillain-Barre Syndrome Hypersensitivity Hypoalbuminemia Hyponatremia Infection Lung Lymphocyte Neck Neutrophil Ophthalmoplegia Paralysis, Facial Patient Discharge Patients Peripheral Nervous System Diseases Plasma Plasma Albumin Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Prognosis Shoulder Sodium Sputum Upper Respiratory Infections Wheelchair X-Ray Computed Tomography

Top products related to «Dysarthria»

1
Sas v9 by SAS Institute
Sourced in United States, Austria, United Kingdom, Cameroon, Belgium, Israel, Japan, Australia, France, Germany
SAS v9.4 is a software product developed by SAS Institute. It is a comprehensive data analysis and statistical software suite. The core function of SAS v9.4 is to provide users with tools for data management, analysis, and reporting.
2
Spss ver 22 by IBM
Sourced in United States, Japan
SPSS ver. 22.0 is a statistical software package developed by IBM. It is designed for advanced analytics, data management, and reporting. The software provides a wide range of statistical analysis tools and techniques, including descriptive statistics, regression analysis, and hypothesis testing.
3
Spss version by IBM
Sourced in United States, United Kingdom, Japan, Germany
SPSS is a software package used for statistical analysis. It provides a graphical user interface and a robust set of tools for data manipulation, analysis, and visualization. SPSS is designed to handle a wide range of data types and supports a variety of statistical techniques, including regression analysis, factor analysis, and time series analysis.
4
Geltrex ldev free hesc qualified reduced growth factor basement membrane matrix by Thermo Fisher Scientific
Sourced in United States
Geltrex LDEV-Free hESC-qualified Reduced Growth Factor Basement Membrane Matrix is a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm (EHS) mouse sarcoma cells. It is designed to provide a complex mixture of extracellular matrix proteins and growth factors to support the growth and differentiation of human embryonic stem cells.
5
Digital audio tape deck dtc ze700 by Sony
The Digital Audio Tape Deck DTC-ZE700 is a professional-grade audio recording and playback device. It supports the Digital Audio Tape (DAT) format and provides high-quality digital audio recording and reproduction capabilities.
6
Mza 900 p by Sennheiser
The Sennheiser MZA 900 P is a microphone preamplifier designed for professional audio applications. It provides gain and impedance matching for microphones, allowing them to be connected to a variety of audio equipment. The MZA 900 P features balanced inputs and outputs, as well as phantom power for condenser microphones.
7
Nicolet cortical stimulator by Natus
The Nicolet Cortical Stimulator is a medical device designed for direct cortical stimulation during neurosurgical procedures. It provides controlled electrical stimulation to the cerebral cortex to elicit neurophysiological responses, which can be used to map and identify critical brain areas.
8
Ocs2 ojemann cortical stimulator by Integra LifeSciences
Sourced in United States
The OCS2 Ojemann cortical stimulator is a medical device designed for the electrical stimulation of the cerebral cortex. It provides controlled electrical stimulation to specific areas of the brain during neurosurgical procedures. The core function of the OCS2 is to assist healthcare professionals in the localization and mapping of eloquent brain regions to help guide surgical decision-making.
9
Spss statistics version 20 by IBM
Sourced in United States, Japan, United Kingdom, Germany, Austria, Belgium
SPSS Statistics version 20 is a comprehensive software package for statistical analysis. It provides a wide range of statistical procedures and techniques for data management, analysis, and presentation. The software is designed to handle a variety of data types and can be used for tasks such as descriptive statistics, regression analysis, and hypothesis testing.
10
Hsp 4 by Sennheiser
Sourced in Germany
The Sennheiser HSP 4 is a professional-grade headset microphone. It is designed for clear and reliable audio capture in a variety of applications.

More about "Dysarthria"

Dysarthria is a speech disorder characterized by impaired articulation and pronunciation, often resulting from neurological conditions or diseases.
This speech impairment can be caused by a variety of underlying factors, including neuromuscular disorders, brain injuries, or other neurological problems.
Related terms and subtopics: - Speech disorders: Apraxia of speech, Anarthria, Aphasia - Neurological conditions: Parkinson's disease, Stroke, Multiple sclerosis, Amyotrophic lateral sclerosis (ALS) - Articulation and pronunciation difficulties: Slurred speech, Mumbled speech, Distorted vowels/consonants - Diagnostic tools: Electromyography (EMG), Magnetic resonance imaging (MRI), Electroencephalography (EEG) - Treatments and management strategies: Speech therapy, Oral motor exercises, Dysarthia-specific communication devices, Medication management The PubCompare.ai platform leverages AI-powered technology to help researchers and clinicians efficiently locate the most effective protocols and treatments for dysarthria from published literature, preprints, and patents.
By empowering users to compare and identify the optimal interventions, the platform streamlines the research process and accelerates the discovery of effective management strategies for this speech impairment.
Experience the power of AI-driven protocol comparisons to advance your dysarthria research today.
Discover how PubCompare.ai can optimize your research by providing access to the latest and most effective treatments, products, and management strategies.